View Cart  

Novartis Heart-Failure Drug Reduces Deaths in Phase III Study

A A
Novartis’ experimental heart failure drug RLX030 reduced deaths in patients with acute heart failure (AHF) in a Phase III study, setting it up for a 2013 regulatory submission.

To View This Article:

Login

Subscribe To Drug Industry Daily